{"organizations": [], "uuid": "767b9693e749baf346428e00a15a01ca88578016", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/4", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/20/business-wire-immunogen-announces-conference-call-to-discuss-its-first-quarter-2018-operating-results.html", "country": "US", "domain_rank": 767, "title": "ImmunoGen Announces Conference Call to Discuss Its First Quarter 2018 Operating Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.005, "site_type": "news", "published": "2018-04-20T16:00:00.000+03:00", "replies_count": 0, "uuid": "767b9693e749baf346428e00a15a01ca88578016"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/20/business-wire-immunogen-announces-conference-call-to-discuss-its-first-quarter-2018-operating-results.html", "ord_in_thread": 0, "title": "ImmunoGen Announces Conference Call to Discuss Its First Quarter 2018 Operating Results", "locations": [], "entities": {"persons": [], "locations": [{"name": "mass.", "sentiment": "none"}, {"name": "waltham", "sentiment": "none"}], "organizations": [{"name": "immunogen", "sentiment": "negative"}, {"name": "company", "sentiment": "none"}, {"name": "immunogen, inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 4, 2018 to discuss its first quarter operating results. Management also will provide a brief update on the business.\nConference Call Information\nTo access the live call by phone, dial 719-325-4799; the conference ID is 2070974. The call may also be accessed through the Investors section of the Company’s website, www.immunogen.com . Following the webcast, a replay of the call will be available at the same location through May 18, 2018.\nAbout ImmunoGen, Inc.\nImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. The Company’s lead product candidate, mirvetuximab soravtansine, is in the Phase 3 FORWARD I trial for FRα-positive platinum-resistant ovarian cancer, and is in the Phase 1b/2 FORWARD II trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC technology is also used in Roche's marketed product, Kadcyla ® , and in programs in development by Amgen, Bayer, Biotest, CytomX, Debiopharm, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at www.immunogen.com .\nKadcyla ® is a registered trademark of Genentech, a member of the Roche Group.\nView source version on businesswire.com : https://www.businesswire.com/news/home/20180420005134/en/\nFor Investors\nImmunoGen, Inc.\nSarah Kiely, 781-895-0600\nsarah.kiely@immunogen.com\nor\nFor Media\nImmunoGen, Inc.\nCourtney O'Konek, 781-895-0600\ncourtney.okonek@immunogen.com\nor\nFTI Consulting, Inc.\nRobert Stanislaro, 212-850-5657\nrobert.stanislaro@fticonsulting.com\nSource: ImmunoGen, Inc.", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.immunogen.com&esheet=51792314&newsitemid=20180420005134&lan=en-US&anchor=ImmunoGen%2C+Inc.&index=1&md5=bfec079536707490783276cfab0e4560", "https://www.businesswire.com/news/home/20180420005134/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.immunogen.com%2F&esheet=51792314&newsitemid=20180420005134&lan=en-US&anchor=www.immunogen.com&index=3&md5=a916ebb7b4b747bad29521d2b096dea7", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.immunogen.com&esheet=51792314&newsitemid=20180420005134&lan=en-US&anchor=www.immunogen.com&index=2&md5=9bb8d2c6a891c0fd167e7006a16ed49d"], "published": "2018-04-20T16:00:00.000+03:00", "crawled": "2018-04-20T17:46:48.009+03:00", "highlightTitle": ""}